Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults



Pfizer Inc.

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age or older.

Related News

Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 9, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics a...


PRESS RELEASE Corporate Announcements

World Health Organization Updated Emergency Use Listing Recommends Johnson & Johnson COVID-19 Vaccine for Booster Use

April 4, 2022 - The World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for the Johnson & Johnson COVID-19 vaccine, reco...


PRESS RELEASE Corporate Announcements

Moderna vaccine slightly more effective than Pfizer vaccine in preventing COVID-19 infection, hospitalization, and death

Boston, MA – Compared with the Pfizer COVID-19 vaccine, the Moderna COVID-19 vaccine has a slightly lower risk of COVID-19 outcomes, including documen...


PRESS RELEASE Research Findings

Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) today announced positive top-line results from a Phase 3 study (B7471026) describing the safety and...


PRESS RELEASE Research Findings

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509,1710

15th,17th floor South Sathorn road Yannawa

Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email :

Website :


Contact Us